Comparison of Two Kinds of Intraperitoneal Chemotherapy Following Complete Cytoreductive Surgery of Colorectal Peritoneal Carcinomatosis

Élias, Dominique; Benizri, Emmanuel; Pietrantonio, Daniela Di; Menegon, Paola; Malka, David; Raynard, Bruno

doi:10.1245/s10434-006-9167-9

Cited by 112 publications

(77 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past debulking surgery accompanied by systemic pH incompatibility 5FU cannot be mixed with OX for intraperitoneal use [17,18] . Despite its advantageous phar macokinetic properties MMCinduced leukopenia due to bone marrow toxicity after HIPEC is a known and frequently encountered sideeffect of this treatment [19] .…”

Section: Discussionmentioning

confidence: 99%

Incidence of leukopenia after intraperitonealvscombined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei

Horvath¹,

Beckert²,

Struller³

et al. 2016

WJGPT

View full text Add to dashboard Cite

AIM:To investigate the clinical impact of post-hyperthermic intraperitoneal chemotherapy (HIPEC) leukopenia, intraperitoneal and combined intravenous/intraperitoneal drug administrations were compared. METHODS:Two patient cohorts were retrospectively analyzed regarding the incidence of postoperative leukopenia. The first cohort (n = 32) received Mitomycin C (MMC)-based HIPEC intraperitoneally (35 mg/m² for 90 min) and the second cohort (n = 10) received a bidirectional therapy consisting of oxaliplatin (OX) (300 mg/m 2 for 30 min) intraperitoneally and 5-fluorouracil (5-FU) 400 mg/m² plus folinic acid 20 mg/m² intravenously. The following data were collected retrospectively: Age, sex, length of operation, length of hospital stay, amount of resection including extent of peritonectomy, peritoneal cancer index, CC (completeness of cytoreduction)-status and leukocyte-count before cytoreductive surgery (CRS) and HIPEC, on days 3, 7 and 14 after CRS and HIPEC. HIPEC leukopenia was defined as < 4000 cells/m³. RESULTS:Leukopenia occurred statistically more often in the MMC than in the OX/5-FU-group (10/32 vs 0/10; P = 0.042). Leukopenia set-on was on day 7 after CRS and MMC-HIPEC and lasted for two to three days. Three patients (33%) required medical treatment. Patients affected by leukopenia were predominantly female (7/10 patients) and older than 50 years (8/10 patients Author contributions: Horvath P designed and performed the research and wrote the paper; Beckert S performed the statistical analysis and supervised the report; Struller F contributed to the research; Königsrainer A supervised the report; Königsrainer I interpreted the data, supervised the report and made the final revision of the paper.Institutional review board statement: We confirm that retrospective data collection and dealing with personal data was conducted in accordance to the guidelines of the local ethics committee. Informed consent statement:We confirm that all patients gave written or oral informed consent prior to their inclusion. Conflict-of-interest statement:We declare that we have no conflict of interest. Data sharing statement: No additional data are available.Open-Access: This article is an openaccess article which was selected by an inhouse editor and fully peerreviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: http://creativecommons.org/ licenses/bync/4.0/ CONCLUSION: Surgeons must be aware that there is a higher incidence of postoperative leukopenia in MMCbased HIPEC protocols primarily affecting females and older patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of leukopenia after intraperitonealvscombined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei

Horvath¹,

Beckert²,

Struller³

et al. 2016

WJGPT

View full text Add to dashboard Cite

show abstract

“…Elias et al compared two groups of patients with colorectal carcinomatosis where one was treated with EPIC using 5FU and mitomycin C and the other with HIPEC using oxaliplatin 43°C. Morbidity, mortality, recurrence rate and overall survival favoured the HIPEC group [19,22].…”

Section: Early Postoperative Intraperitoneal Chemotherapymentioning

confidence: 94%

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy

Valle

Alzahrani

Sugarbaker

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) combined have been recognized as standard of care for treatment of a subset of patients with peritoneal carcinomatosis (PC). The aim of CRS is to eliminate all macroscopic disease through a series of visceral resections followed by targeting any residual microscopic disease with intraperitoneal chemotherapy, exposing the peritoneal surfaces to a high concentration of chemotherapy with a lower systemic toxicity. Different regimes of intraperitoneal chemotherapy include HIPEC, early postoperative intraperitoneal chemotherapy (EPIC) and bidirectional chemotherapy. The efficacy and modality of treatment with intraperitoneal chemotherapy is dependent on multiple factors including the chosen cytotoxic agent and its pharmacokinetics and pharmacodynamics. There is no standardized methodology for intraperitoneal chemotherapy administration. This review will discuss the pharmacological principles of the various intraperitoneal chemotherapy techniques.

show abstract

“…Some authors have reported improved survival with hyperthermia (but always in retrospective studies) for patients with pseudomyxoma peritonei and colorectal PC. 7,25 Because of its design, no firm conclusions can be drawn regarding PIC techniques from this retrospective study. Institutional experience and expertise are likely to be the most important variables in limiting procedurerelated toxicity and improving survival.…”

Section: Treatment Of Peritoneal Carcinomatosis/glehen Et Almentioning

confidence: 95%

“…[1][2][3][4][5] Over the past 2 decades, novel therapeutic approaches to peritoneal carcinomatosis (PC) have emerged that combine cytoreductive surgery and peritonectomy procedures 6 with perioperative intraperitoneal chemotherapy (PIC), including hyperthermic intraperitoneal chemotherapy (HIPEC) and/or early postoperative intraperitoneal chemotherapy (EPIC). [7][8][9] Theoretically, cytoreductive surgery is performed to treat macroscopic disease, and PIC is used to treat microscopic residual disease with the objective of removing disease completely in a single procedure. Many consider it the standard of care for diseases like pseudomyxoma peritonei or peritoneal mesothelioma.…”

mentioning

confidence: 99%

Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy

Gléhen

Gilly

Boutitie

et al. 2010

Cancer

Self Cite

468

289

View full text Add to dashboard Cite

Acrylic acid and sodium styrene sulfonate were grafted onto high‐density polyethylene (HDPE) membrane by preirradiation, and we prepared a cation exchange membrane with strong acid and weak acid groups. The HCl was used as an additive to change the pH of grafting system, and the effect of pH on grafting yield was studied. In simultaneous radiation method, the overall grafting yield (Gt) and grafting yield of SSS onto HDPE (Gs) increased with decreasing of pH. In preirradiation method, Gt and Gs first increased with decreasing of pH, and the highest grafting yield was observed at pH = 2.80, then decreased if we further reduced the pH of the grafting system. Viscosity of grafting system was changed owing to the change of the ionization degree of polyacrylic acid in the presence of HCl, so that diffuse rate of monomers into matrix was affected. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 103: 2622–2626, 2007

show abstract

Comparison of Two Kinds of Intraperitoneal Chemotherapy Following Complete Cytoreductive Surgery of Colorectal Peritoneal Carcinomatosis

Abstract: This study provides strong arguments indicating that IPCH with oxaliplatin is better tolerated than EPIC with mitomycin C and 5-FU, and is twice as efficient in curing residual peritoneal carcinomatosis measuring less than 1 mm.

Cited by 112 publications

References 12 publications

Incidence of leukopenia after intraperitonealvscombined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei

Incidence of leukopenia after intraperitonealvscombined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy

Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy

Contact Info

Product

Resources

About